Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.19
Views: 842

Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Prasad Adusumilli gives a press conference at AACR 2019 on results from a phase I clinical trial showing that CAR T cell therapy, targeting the protein mesothelin, produced anti-tumour activity with no evidence of major toxicity when treating patients with advanced solid tumours.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation